CN116555339A - NHEJ substrate and preparation method and application thereof - Google Patents
NHEJ substrate and preparation method and application thereof Download PDFInfo
- Publication number
- CN116555339A CN116555339A CN202310347927.1A CN202310347927A CN116555339A CN 116555339 A CN116555339 A CN 116555339A CN 202310347927 A CN202310347927 A CN 202310347927A CN 116555339 A CN116555339 A CN 116555339A
- Authority
- CN
- China
- Prior art keywords
- nhej
- substrate
- chain primer
- sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000758 substrate Substances 0.000 title claims abstract description 92
- 230000011559 double-strand break repair via nonhomologous end joining Effects 0.000 title claims abstract description 69
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 108020004414 DNA Proteins 0.000 claims abstract description 68
- 102000053602 DNA Human genes 0.000 claims abstract description 51
- 239000012634 fragment Substances 0.000 claims abstract description 29
- 108700043045 nanoluc Proteins 0.000 claims abstract description 17
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 15
- 230000033616 DNA repair Effects 0.000 claims abstract description 12
- 238000001976 enzyme digestion Methods 0.000 claims abstract description 12
- 238000012216 screening Methods 0.000 claims abstract description 8
- 108010061982 DNA Ligases Proteins 0.000 claims abstract description 6
- 102000012410 DNA Ligases Human genes 0.000 claims abstract description 6
- 238000000137 annealing Methods 0.000 claims abstract description 6
- 239000013600 plasmid vector Substances 0.000 claims abstract description 6
- 238000012827 research and development Methods 0.000 claims abstract description 5
- 210000004899 c-terminal region Anatomy 0.000 claims description 21
- 230000000295 complement effect Effects 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 238000007877 drug screening Methods 0.000 claims description 2
- 230000008439 repair process Effects 0.000 abstract description 64
- 230000006378 damage Effects 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 9
- 208000027418 Wounds and injury Diseases 0.000 abstract description 5
- 208000014674 injury Diseases 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 33
- 230000037361 pathway Effects 0.000 description 29
- 229940126071 ART558 Drugs 0.000 description 18
- YHMDHAMZFMNMTF-MSOLQXFVSA-N C(#N)C=1C(=NC(=CC=1C(F)(F)F)C)N1[C@@H]([C@@H](CC1)O)C(=O)N(C=1C=C(C=CC=1)C)C Chemical compound C(#N)C=1C(=NC(=CC=1C(F)(F)F)C)N1[C@@H]([C@@H](CC1)O)C(=O)N(C=1C=C(C=CC=1)C)C YHMDHAMZFMNMTF-MSOLQXFVSA-N 0.000 description 17
- 230000000052 comparative effect Effects 0.000 description 14
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 238000001890 transfection Methods 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 239000013598 vector Substances 0.000 description 6
- 230000005778 DNA damage Effects 0.000 description 5
- 231100000277 DNA damage Toxicity 0.000 description 5
- 230000006801 homologous recombination Effects 0.000 description 5
- 238000002744 homologous recombination Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 102100029766 DNA polymerase theta Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000033590 base-excision repair Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000033607 mismatch repair Effects 0.000 description 3
- 229910052754 neon Inorganic materials 0.000 description 3
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 3
- 230000020520 nucleotide-excision repair Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 102100022204 DNA-dependent protein kinase catalytic subunit Human genes 0.000 description 2
- 101710157074 DNA-dependent protein kinase catalytic subunit Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 101001094659 Homo sapiens DNA polymerase kappa Proteins 0.000 description 2
- 101000865085 Homo sapiens DNA polymerase theta Proteins 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000012361 double-strand break repair Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- -1 pol gamma Proteins 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- KIAPWMKFHIKQOZ-UHFFFAOYSA-N 2-[[(4-fluorophenyl)-oxomethyl]amino]benzoic acid methyl ester Chemical compound COC(=O)C1=CC=CC=C1NC(=O)C1=CC=C(F)C=C1 KIAPWMKFHIKQOZ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- 108091060290 Chromatid Proteins 0.000 description 1
- 102000008158 DNA Ligase ATP Human genes 0.000 description 1
- 108010060248 DNA Ligase ATP Proteins 0.000 description 1
- 102100039524 DNA endonuclease RBBP8 Human genes 0.000 description 1
- 108050008316 DNA endonuclease RBBP8 Proteins 0.000 description 1
- 108010061914 DNA polymerase mu Proteins 0.000 description 1
- 108010093204 DNA polymerase theta Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 229940126289 DNA-PK inhibitor Drugs 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
- 101100388059 Drosophila melanogaster PolQ gene Proteins 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102100029075 Exonuclease 1 Human genes 0.000 description 1
- 102000016627 Fanconi Anemia Complementation Group N protein Human genes 0.000 description 1
- 108010067741 Fanconi Anemia Complementation Group N protein Proteins 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 101000918264 Homo sapiens Exonuclease 1 Proteins 0.000 description 1
- 101000829958 Homo sapiens N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102100023315 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Human genes 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 1
- 108700018273 Rad30 Proteins 0.000 description 1
- 102000002490 Rad51 Recombinase Human genes 0.000 description 1
- 108010068097 Rad51 Recombinase Proteins 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 101100117496 Sulfurisphaera ohwakuensis pol-alpha gene Proteins 0.000 description 1
- 102100036976 X-ray repair cross-complementing protein 6 Human genes 0.000 description 1
- 101710124907 X-ray repair cross-complementing protein 6 Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940125528 allosteric inhibitor Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004756 chromatid Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000006846 excision repair Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000006780 non-homologous end joining Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000007084 physiological dysfunction Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
- C12Y113/12—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)(1.13.12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention relates to the technical field of DNA repair, in particular to a NHEJ substrate and a preparation method and application thereof, wherein the preparation method comprises the following steps: s1, connecting Nanoluc, SV40 and CMV genes to a plasmid vector through enzyme digestion to prepare a dsDNA fragment sequence; s2, after annealing treatment is carried out on the dsDNA fragment sequence prepared in the step S1, connecting one end of a Nanoluc gene in the dsDNA fragment sequence with an N-end long-chain primer and an N-end short-chain primer, and connecting one end of a CMV gene with a C-end long-chain primer and a C-end short-chain primer to prepare a partially double-stranded DNA; s3, connecting the partially double-stranded DNA obtained in the step S2 by DNA ligase to obtain the NHEJ substrate of the double-stranded DNA. The NHEJ substrate prepared by the invention can specifically identify the NHEJ injury repair path in cells, has wide injury repair range and high efficiency, and is beneficial to the screening and research and development of different subsequent medicines.
Description
Technical Field
The invention relates to the technical field of DNA repair, in particular to a NHEJ substrate and a preparation method and application thereof.
Background
DNA repair (dnasairing) is a reaction of cells after they have been damaged to DNA, which may restore the DNA structure as it is, re-performing its original function; however, there are cases where DNA damage is not completely eliminated, but cells are allowed to survive the DNA damage. It is possible that damage that remains without complete repair will manifest itself under certain conditions (e.g., cancerous cells, etc.), but if the cells do not have such repair function, it is not possible to cope with the frequently occurring DNA damage events.
DNA damage can cause serious physiological dysfunction, and thus, different repair methods have been studied for different types of DNA damage. DNA repair in eukaryotes is mainly of 4 types: nucleotide Excision Repair (NER), base Excision Repair (BER), mismatch repair (MMR), and Double Strand Break Repair (DSBR).
NER and BER are collectively called excision repair, and damaged parts can be excised from DNA molecules, and intact DNA double strands are synthesized by using undamaged DNA single strands as templates to complete the repair process. MMR can repair false pairings generated in DNA replication; DSB is a serious injury that results in loss and rearrangement of genomic sequences, and there are mainly three repair pathways:
(1) Homologous Recombination (HR) the activity of HR is limited to the S and G2 phases of the cell cycle. HR requires DNA excision, where nuclear degradation of DSB yields 3' ss DNA overhang, which is initiated by MRE11-RAD50-NBS1 complex (MRN) together with CtIP, followed by prolonged excision catalyzed by EXO1 and DNA 2-BLM. Following excision, the 3' ssdna tail is bound by RPA, followed by activation of RAD51 by the action of BRCA2 and PALB2 (RAD 51 nuclear fiber mediated strand invasion and homology searches on sister chromatids). Finally, the missing nucleotide is filled by copying undamaged staining monomers, and the repair of the minimal change to the original sequence is completed, so that the HR repair efficiency is low and the speed is low.
(2) Polymer theta-mediated end joining (TMEJ): TMEJ is a backup way to repair excised DSB, which is initiated by 5 'to 3' excision factors, involving PARP1, DNA ligase III and polymerase A family enzymes, DNA polymerase θ encoded by PolQ, polθ initiates DNA synthesis with its polymerase domain to fill the gap, and then ligates annealed DSB ends to complete repair. TMEJ is responsible for only a small portion of DNA repair, can complete less than 10% of DNA repair compared to other repair damage pathways, is less efficient, and is not as effective as other repair pathways in experiments where in vitro and cellular DNA repair DSB is deemed to be successful.
(3) Canonical nonhomologous end joining (c-NHEJ) NHEJ is the major repair pathway in mammalian cells, repairing up to 80% of DSB. After Ku70/80 (Ku) heterodimers recognize the cleaved DNA ends, the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) stabilizes the DNA ends, initiating a canonical end ligation pathway. The DNA-PK complex phosphorylates various factors to facilitate end ligation by ligase 4 (Lig 4). NHEJ uses additional end processing enzymes such as Artemis, PNKPT1 and X-Pol lambda and Pol mu to closely align and ligate the cleaved DNA ends.
Therefore, it is necessary to develop a substrate for NHEJ repair that is capable of specifically recognizing NHEJ damage repair pathways in cells.
Disclosure of Invention
The invention aims to provide a NHEJ substrate, a preparation method and application thereof, wherein the NHEJ substrate can specifically identify a NHEJ injury repair path in cells, has a wide injury repair range and high efficiency, and is beneficial to the subsequent screening and research and development of different types of medicaments.
In a first aspect of the invention, there is provided a method of preparing a NHEJ substrate comprising the steps of:
s1, connecting Nanoluc, SV40 and CMV genes to a plasmid vector through enzyme digestion to prepare a dsDNA fragment sequence;
s2, after annealing treatment is carried out on the dsDNA fragment sequence prepared in the step S1, connecting one end of a Nanoluc gene in the dsDNA fragment sequence with an N-end long-chain primer and an N-end short-chain primer, and connecting one end of a CMV gene with a C-end long-chain primer and a C-end short-chain primer to prepare a partially double-stranded DNA;
s3, connecting the partially double-stranded DNA obtained in the step S2 by DNA ligase to obtain the NHEJ substrate of the double-stranded DNA.
Preferably, the N-terminal long-chain primer and the C-terminal long-chain primer have 10bp homologous complementary sequences.
Preferably, the N-terminal long-chain primer sequence is shown in SEQ ID NO:1, the sequence of the N-terminal short-chain primer is shown as SEQ ID NO:2, the sequence of the C-terminal long-chain primer is shown as SEQ ID NO:3, the sequence of the C-terminal short-chain primer is shown as SEQ ID NO: 4.
Preferably, the N-terminal long-chain primer and the C-terminal long-chain primer have 20bp homologous complementary sequences.
Preferably, the N-terminal long-chain primer sequence is shown in SEQ ID NO:6, the sequence of the N-terminal short-chain primer is shown as SEQ ID NO:7, the sequence of the C-terminal long-chain primer is shown as SEQ ID NO:8, the sequence of the C-terminal short-chain primer is shown as SEQ ID NO: shown at 9.
Preferably, the dsDNA fragment sequence is set forth in SEQ ID NO: shown at 5.
In a second aspect of the present invention, there is provided a NHEJ substrate obtained by the above method for preparing a NHEJ substrate, wherein the NHEJ substrate has a 10bp or 20bp homologous complementary sequence.
Preferably, the NHEJ substrate sequence is as shown in SEQ ID NO: shown at 10.
Preferably, the NHEJ substrate sequence is as shown in SEQ ID NO: 11.
In a third aspect of the invention, an NHEJ substrate obtained by the above preparation method of an NHEJ substrate or an application of the above NHEJ substrate in DNA repair, drug screening and research and development, and new target screening is provided.
The beneficial effects are that:
the NHEJ substrate obtained by the preparation method of the NHEJ substrate can specifically identify a NHEJ damage repair path in cells, has a wide damage repair range and high efficiency, and is beneficial to the screening and research and development of different subsequent drugs, such as covalent small molecules, protein degradation inducers, RNA drugs and other drugs; the potential application value can deeply explore related targets of the NHEJ repair pathway, can be combined with a screening method of a library, explores new targets of synergistic effect and compensation effect in the pathway, and provides for future research work of combined drug and drug resistance compensation.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings that are needed in the description of the embodiments or the prior art will be briefly described, and it is obvious that the drawings in the description below are some embodiments of the present invention, and other drawings can be obtained according to the drawings without inventive effort for a person skilled in the art.
FIG. 1 is a graph showing comparison of fluorescence signal values of substrates prepared in example I and comparative example of the present invention 5 hours after transfection of cells, wherein DMSO is used as a control, pepossertib is used as an NHEJ repair pathway inhibitor, and ART558 is used as a TMEJ repair pathway inhibitor;
FIG. 2 is a graph showing comparison of fluorescence signal values of substrates prepared in example I and comparative example of the present invention 24 hours after cell transfection, wherein DMSO is used as a control, pepossertib is used as an NHEJ repair pathway inhibitor, and ART558 is used as a TMEJ repair pathway inhibitor;
FIG. 3 is a graph showing comparison of the inhibition of repair of substrates prepared in example I and comparative example of the present invention by compounds 5 hours after cell transfection, wherein DMSO is used as a control, pepossertib is used as an NHEJ repair pathway inhibitor, and ART558 is used as a TMEJ repair pathway inhibitor;
FIG. 4 is a graph showing comparison of the inhibition of repair of substrates prepared in example I and comparative example of the present invention by compounds 24 hours after cell transfection, wherein DMSO is used as a control, pepossertib is used as an NHEJ repair pathway inhibitor, and ART558 is used as a TMEJ repair pathway inhibitor;
FIG. 5 is a graph showing inhibition of repair of substrates prepared according to comparative examples of the present invention by different concentrations of Pepossertib (M3814);
FIG. 6 is a graph showing inhibition of repair of a substrate prepared in example one of the present invention by different concentrations of Pepossertib (M3814);
FIG. 7 is a graph showing inhibition of repair of a substrate prepared in example II by Pepossertib (M3814) at various concentrations;
FIG. 8 is a graph showing that repair of a substrate prepared in the comparative example of the present invention is inhibited by ART558 at various concentrations;
FIG. 9 is a graph showing the inhibition of repair of a substrate prepared in accordance with the example of the present invention by ART558 at various concentrations;
FIG. 10 is a graph showing that repair of a substrate prepared in example II of the present invention is inhibited by ART558 at various concentrations.
Detailed Description
It should be noted that the following detailed description is illustrative and is intended to provide further explanation of the present application. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs.
It is noted that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of example embodiments in accordance with the present application. As used herein, the singular forms also include the plural unless the context clearly indicates otherwise, and furthermore, it is to be understood that when the terms "comprises" and/or "comprising" are used in this specification, they specify the presence of stated features, steps, operations, devices, components, and/or combinations thereof.
The technical solutions of the present invention will be clearly and completely described in connection with the embodiments, and it is apparent that the described embodiments are some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Example 1
The embodiment provides a preparation method of a NHEJ substrate, which comprises the following steps:
s1, preparation of dsDNA fragment sequences: the Nanoluc, SV40 and CMV genes are connected to a plasmid vector through enzyme digestion to prepare a dsDNA fragment sequence;
specifically, the Nanoluc, SV40 and CMV genes are connected to a pcDNA3.1 vector by enzyme digestion, the vector is amplified, and the amplified plasmid is subjected to double enzyme digestion by XhoI and HindIII to prepare a dsDNA fragment sequence.
S2, preparing a partially double-stranded DNA: after annealing treatment is carried out on the dsDNA fragment sequence prepared in the step S1, one end of a specific Nanoluc gene in the dsDNA fragment sequence is connected with an N-end long-chain primer and an N-end short-chain primer, and one end of a CMV promoter gene is connected with a C-end long-chain primer and a C-end short-chain primer, so that a partially double-stranded DNA is prepared;
s3, preparing a NHEJ detection substrate: and (3) ligating the partially double-stranded DNA prepared in the step (S2) by using T4DNA ligase to prepare a NHEJ substrate of the double-stranded DNA.
In this example, the N-terminal long-chain primer and the C-terminal long-chain primer have 10bp homologous complementary sequences.
In this example, the N-terminal long-chain primer sequence is: TCGAGGACTTGGTCCAGGTTG TAGCCGGCTGTCTGTCGCCAGTCCCCAACGAAATCTTCGAGTGTGAAGACCATGCT (SEQ ID NO: 1), the N-terminal short-chain primer sequence is: GCCGGCTACAAC CTGGACCAAGTCC (SEQ ID NO: 2), the C-terminal long-chain primer sequence is: AGCTTTAA CTAGAGAACCCACTGCTTACTGGCTTATCGAAATTAATACGACTCACTA TAGGGAGACCCAAGCATGGTCT (SEQ ID NO: 3), the C-terminal short-chain primer sequence is: CCAGTAAGCAGTGGGTTCTCTAGTTAA (SEQ ID NO: 4), wherein the homology and complementarity at the dash-dot line with AGACCATGCT and AGCATGGTCT are 10 bp.
In this example, the dsDNA fragment sequence is set forth in SEQ ID NO: shown at 5.
Example two
The embodiment provides a preparation method of a NHEJ substrate, which comprises the following steps:
s1, preparation of dsDNA fragment sequences: the Nanoluc, SV40 and CMV genes are connected to a plasmid vector through enzyme digestion to prepare a dsDNA fragment sequence;
specifically, the Nanoluc, SV40 and CMV genes are connected to a pcDNA3.1 vector by enzyme digestion, the vector is amplified, and the amplified plasmid is subjected to double enzyme digestion by XhoI and HindIII to prepare a dsDNA fragment sequence.
S2, preparing a partially double-stranded DNA: after annealing treatment is carried out on the dsDNA fragment sequence prepared in the step S1, one end of a specific Nanoluc gene in the dsDNA fragment sequence is connected with an N-end long-chain primer and an N-end short-chain primer, and one end of a CMV promoter gene is connected with a C-end long-chain primer and a C-end short-chain primer, so that a partially double-stranded DNA is prepared;
s3, preparing a NHEJ detection substrate: and (3) ligating the partially double-stranded DNA prepared in the step (S2) by using T4DNA ligase to prepare a NHEJ substrate of the double-stranded DNA.
In this example, the N-terminal long-chain primer and the C-terminal long-chain primer have 20bp homologous complementary sequences.
In this example, the N-terminal long-chain primer sequence is: TCGAGGACTTGGTCCAGGTTG TAGCCGGCTGTCTGTCGCCAGTCCCCAACGAAATCTTCGAGTGTGAAGACCATGCTTGGGT (SEQ ID NO: 6), the N-terminal short-chain primer sequence is: GCCGGCT ACAACCTGGACCAAGTCC (SEQ ID NO: 7), the C-terminal long-chain primer sequence is: AG CTTTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAATTAATACGAC TCACTATAGGGAGACCCAAGCATGGTCTTCACA (SEQ ID NO: 8), the C-terminal short-chain primer sequence is: CCAGTAAGCAGTGGGTTCTCTAGTTAA (SEQ ID NO: 9), wherein TGTGAAGACCATGCTTGGGT and ACCCAAGCATGGTC TTCACA at the dash are 20bp homologous complementary sequences.
In this example, the dsDNA fragment sequence is set forth in SEQ ID NO: shown at 5.
Example III
This example provides a NHEJ substrate obtained by the preparation method of NHEJ substrates of examples one to two, which has a 10bp or 20bp homologous complementary sequence.
In this example, the NHEJ substrate sequence obtained by the preparation method of example one is as set forth in SEQ ID NO: shown at 10.
In this example, the NHEJ substrate sequence obtained by the preparation method of example two is shown in SEQ ID NO: 11.
Comparative example
The present example provides a method for preparing a substrate comprising the steps of:
s1, preparation of dsDNA fragment sequences: the Nanoluc, SV40 and CMV genes are connected to a plasmid vector through enzyme digestion to prepare a dsDNA fragment sequence;
specifically, the Nanoluc, SV40 and CMV genes are connected to a pcDNA3.1 vector by enzyme digestion, the vector is amplified, and the amplified plasmid is subjected to double enzyme digestion by XhoI and HindIII to prepare a dsDNA fragment sequence.
S2, preparing a partially double-stranded DNA: after annealing treatment is carried out on the dsDNA fragment sequence prepared in the step S1, one end of a specific Nanoluc gene in the dsDNA fragment sequence is connected with an N-end long-chain primer and an N-end short-chain primer, and one end of a CMV promoter gene is connected with a C-end long-chain primer and a C-end short-chain primer, so that a partially double-stranded DNA is prepared;
s3, preparing a substrate: and (3) ligating the partially double-stranded DNA prepared in the step (S2) by using T4DNA ligase to prepare a NHEJ substrate of the double-stranded DNA.
In this example, the N-terminal long-chain primer and the C-terminal long-chain primer have 4bp homologous complementary sequences.
In this example, the N-terminal long-chain primer sequence is: TCGAGGACTTGGTCCAGGTTG TAGCCGGCTGTCTGTCGCCAGTCCCCAACGAAATCTTCGAGTGTGAA GACCAT (SEQ ID NO: 12), the N-terminal short-chain primer sequence is: GCCGGCTACAACCT GGACCAAGTCC (SEQ ID NO: 13), the C-terminal long-chain primer sequence is: AGCTTTAAC TAGAGAACCCACTGCTTACTGGCTTATCGAAATTAATACGACTCACTAT AGGGAGACCCAAGCATGG (SEQ ID NO: 14), the C-terminal short-chain primer sequence is: c CAGTAAGCAGTGGGTTCTCTAGTTAA (SEQ ID NO: 15), wherein CCAT and ATGG at the dash line are 4bp homologous complements.
In this example, the dsDNA fragment sequence is set forth in SEQ ID NO: shown at 5.
Example IV
The embodiment provides a method for detecting the substrate, which comprises the following steps:
1. preparation work
The Neon transfection system was UV sterilized and E2 and R buffers were warmed to room temperature and the complete medium without antibiotics was warmed up in a 37℃water bath.
b. Setting up a Neon transfection system: the electrode cup was inserted into a Neon transfection system pipette and 3mL of E2 buffer was added to the tube.
2. Cell treatment
a. Cell culture: HEK293T cells were cultured using DMEM medium (complete medium) of 10% heat-inactivated fetal bovine serum and 1% antibiotics.
b. Cell treatment: HEK293T cells grown to 80% -90% in T75 flasks were digested with pancreatin and counted.
Injection to ensure the number of passages of cells<20 and less than 100%, the cell viability was as follows>90% suspension, preparation of cell density of 2-3×10 6 about/mL.
Collection of 2X 10 6 HEK293T cells were isolated with DPBS (Mg-free 2+ And Ca 2+ ) The cells were washed once, centrifuged at 1000rpm for 5min, and the supernatant was discarded. Cells were resuspended with 100. Mu.L of R buffer.
c. Preparing a DNA buffer solution: according to the DNA substrate concentration, 2ug of NHEJ substrate prepared in the first and second examples was taken, 10ug of the substrate prepared in the comparative example was taken, and if the substrate volume was less than 10u L, R buffer was added to prepare 10ul of DNA buffer, respectively.
The resuspended cells were all added to the DNA buffer and mixed well.
3. Cell electroporation
100uL of the cell suspension was mixed with 10uL of the DNA substrate suspension, thereby forming a 110uL total system. Thereafter 100uL was aspirated from it using an electrokinetic gun and added to an electrode cup containing 3mL of E2 buffer, and electroporation was started according to the parameters of Table 1.
TABLE 1
| Pulse voltage(V) | 1600 |
| Pulse width(ms) | 10 |
| Pulse times | 3 |
Placing the transfected experimental cells obtained in the step 3 in a DMEM culture medium without antibiotics, and fully and uniformly mixing.
4. Substrate detection
a. Cell plating: the transformed cells were harvested and seeded at 40000 cells per well in 384 well plates.
b. The gradient diluted Peposertib was added to the cells in step a, and after 24h the Nanoluc signal was read using an microplate reader.
Pepsertib (M3814) is an orally administered small molecule selective DNA-PK inhibitor capable of blocking DNA-PK kinase activity at nanomolar concentrations, inhibiting its function during DNA repair, leading to the continued presence of DNADSB and subsequent cell death. P epoertib often shows synergy with radiotherapy and DSB-induced chemotherapy by preventing the NHEJ repair pathway, radiotherapy or chemotherapy-induced DNADSB in preclinical studies.
c. ART558 after gradient dilution was added to the cells in step a and the signal value of Nanoluc was read 24h later using an enzyme-labeled instrument.
ART558 is a low molecular weight allosteric inhibitor with the advantage of selectively inhibiting POLQ-mediated major DNA repair pathways, not inhibiting other human DNA polymerases (Pol alpha, pol gamma, pol eta and Pol v), not targeting the NHEJ DNA repair pathway. At the same time ART558 was able to inhibit POLQ-mediated DNA DSB repair with nanomolar potency but was not able to be used to inhibit NHEJ, further demonstrating excellent selectivity of molecules.
The substrate detection results were as follows:
(1) The results of the fluorescent signal value 5 hours after transfection of the cells (FIG. 1) and the fluorescent signal value 24 hours after transfection of the cells (FIG. 2) showed that: cells transfected with the substrate with the 10bp homologous complement prepared in example one produced a higher fluorescence signal value than the substrate with the 4bp homologous complement prepared in comparative example, indicating that the substrate prepared in example one had a higher level of repair and was much greater than the substrate with the 4bp homologous complement prepared in comparative example.
(2) 5 hours after transfection of the cells, the repair of the substrate was indicated by inhibition of ART558, pepossertib compounds (FIG. 3): repair of the substrate with the 4bp homologous complement prepared in the comparative example was not inhibited by any compound, indicating that neither NHEJ nor TMEJ was involved in repair of the substrate at this time point; the repair of the substrate with 10bp homologous complement prepared in example one was inhibited by Peposertib but not by ART558, indicating that the repair of the substrate was now dependent on the NHEJ repair pathway and not on the TMEJ repair pathway.
(3) 24 hours after cell transfection, substrate repair was indicated by inhibition of ART558, peposertib compounds (fig. 4): repair of the substrate with the 4bp homologous complement prepared in the comparative example was inhibited by ART558 and not by Peposertib, indicating that at this time point, the TMEJ repair pathway was involved in repair of the substrate; the repair of the substrate with 10bp homologous complement prepared in example I was inhibited by Pepossertib, and was still not inhibited by ART558, indicating that the repair of the substrate was still dependent on the NHEJ repair pathway.
(4) Inhibition of substrate repair by different concentrations of Peposertib (M3814) compounds indicated: as the Peposertib concentration increased, the substrate repair made in the comparative example was not inhibited by Peposertib (fig. 5), indicating that the substrate repair did not rely on the NHEJ pathway; the substrates prepared in example one and example two showed an increase in inhibition with increasing concentration of Peposertib (fig. 6 to 7), indicating that the substrate repair relied on the NHEJ pathway.
(5) The repair of the substrate is indicated by inhibition of the ART558 compound at different concentrations: as the concentration of a RT558 increases, the substrate repair made by the comparative example is inhibited by ART558 (fig. 8), indicating that the substrate repair relies on the TMEJ pathway; the substrates prepared in example one and example two had reduced inhibition with increasing concentrations of ART558 (fig. 9-10), indicating that substrate repair did not rely on the TMEJ pathway.
Example five
The NHEJ substrates obtained by the preparation method of the NHEJ substrates in the first to second embodiments and the NHEJ substrate in the third embodiment can be used for screening and researching and developing different types of medicines, such as covalent small molecules, protein degradation inducers, RNA medicines and other types of medicines; the potential application value can deeply explore related targets of the NHEJ repair pathway, can be combined with a screening method of a library, explores new targets of synergistic effect and compensation effect in the pathway, and provides for future research work of combined drug and drug resistance compensation.
Finally, it should be noted that: the above embodiments are only for illustrating the technical solution of the present invention, and not for limiting the same; although the invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical scheme described in the foregoing embodiments can be modified or some or all of the technical features thereof can be replaced by equivalents; such modifications and substitutions do not depart from the spirit of the invention.
Claims (10)
1. A method for preparing a NHEJ substrate comprising the steps of:
s1, connecting Nanoluc, SV40 and CMV genes to a plasmid vector through enzyme digestion to prepare a dsDNA fragment sequence;
s2, after annealing treatment is carried out on the dsDNA fragment sequence prepared in the step S1, connecting one end of a Nanoluc gene in the dsDNA fragment sequence with an N-end long-chain primer and an N-end short-chain primer, and connecting one end of a CMV gene with a C-end long-chain primer and a C-end short-chain primer to prepare a partially double-stranded DNA;
s3, connecting the partially double-stranded DNA obtained in the step S2 by DNA ligase to obtain the NHEJ substrate of the double-stranded DNA.
2. The method for preparing a NHEJ substrate according to claim 1, wherein the N-terminal long-chain primer and the C-terminal long-chain primer have 10bp homologous complementary sequences.
3. The method for preparing a NHEJ substrate according to claim 2, wherein the N-terminal long-chain primer sequence is as set forth in SEQ ID NO:1, the sequence of the N-terminal short-chain primer is shown as SEQ ID NO:2, the sequence of the C-terminal long-chain primer is shown as SEQ ID NO:3, the sequence of the C-terminal short-chain primer is shown as SEQ ID NO: 4.
4. The method for preparing a NHEJ substrate according to claim 1, wherein the N-terminal long-chain primer and the C-terminal long-chain primer have 20bp homologous complementary sequences.
5. The method for preparing a NHEJ substrate according to claim 4, wherein the sequence of the N-terminal long-chain primer is shown in SEQ ID NO:6, the sequence of the N-terminal short-chain primer is shown as SEQ ID NO:7, the sequence of the C-terminal long-chain primer is shown as SEQ ID NO:8, the sequence of the C-terminal short-chain primer is shown as SEQ ID NO: shown at 9.
6. The method of claim 1, wherein the dsDNA fragment sequence is set forth in SEQ ID NO: shown at 5.
7. A NHEJ substrate obtained by the method of preparation of a NHEJ substrate according to any one of claims 1-6, which has a 10bp or 20bp homologous complementary sequence.
8. The method of claim 7, wherein the NHEJ substrate sequence is set forth in SEQ ID NO: shown at 10.
9. The method of claim 7, wherein the NHEJ substrate sequence is set forth in SEQ ID NO: 11.
10. Use of a NHEJ substrate obtained by a method of preparation of a NHEJ substrate according to any one of claims 1-6 or a NHEJ substrate according to any one of claims 7-9 in DNA repair, drug screening and research and development and new target screening.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310347927.1A CN116555339B (en) | 2023-04-03 | 2023-04-03 | NHEJ substrate and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310347927.1A CN116555339B (en) | 2023-04-03 | 2023-04-03 | NHEJ substrate and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116555339A true CN116555339A (en) | 2023-08-08 |
| CN116555339B CN116555339B (en) | 2024-01-05 |
Family
ID=87499074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310347927.1A Active CN116555339B (en) | 2023-04-03 | 2023-04-03 | NHEJ substrate and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116555339B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217785A1 (en) * | 2018-05-10 | 2019-11-14 | St. Jude Children's Research Hospital, Inc. | High-throughput method for characterizing the genome-wide activity of editing nucleases in vitro |
| CN112980890A (en) * | 2021-03-19 | 2021-06-18 | 天津市肿瘤医院（天津医科大学肿瘤医院） | Non-homologous end connection detection system and application thereof |
| CN115786339A (en) * | 2022-10-24 | 2023-03-14 | 北京爱思益普生物科技股份有限公司 | TMEJ detection substrate, preparation method and application thereof |
-
2023
- 2023-04-03 CN CN202310347927.1A patent/CN116555339B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217785A1 (en) * | 2018-05-10 | 2019-11-14 | St. Jude Children's Research Hospital, Inc. | High-throughput method for characterizing the genome-wide activity of editing nucleases in vitro |
| CN112980890A (en) * | 2021-03-19 | 2021-06-18 | 天津市肿瘤医院（天津医科大学肿瘤医院） | Non-homologous end connection detection system and application thereof |
| CN115786339A (en) * | 2022-10-24 | 2023-03-14 | 北京爱思益普生物科技股份有限公司 | TMEJ detection substrate, preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| HOWARD H. Y. CHANG 等人: "Non-homologous DNA end joining and alternative pathways to double-strand break repair", NAT REV MOL CELL BIOL., pages 1 - 37 * |
| 张天枫 等人: "DNA依赖性蛋白激酶催化亚基在非同源末端连接修复中作用的研究进展", 癌变·畸变·突变, pages 476 - 480 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116555339B (en) | 2024-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3250689B1 (en) | Methods and compositions for labeling a single-stranded target nucleic acid | |
| Pichon et al. | RNA binding protein/RNA element interactions and the control of translation | |
| Bibiłło et al. | The reverse transcriptase of the R2 non-LTR retrotransposon: continuous synthesis of cDNA on non-continuous RNA templates | |
| CN113939591A (en) | Methods and compositions for editing RNA | |
| US7482332B2 (en) | Telomere-encoding synthetic DNA nanocircles, and their use for the elongation of telomere repeats | |
| CN102124106B (en) | Method for production of cDNA library having reduced content of cDNA clone derived from highly expressed gene | |
| US9464292B2 (en) | Sense oligonucleotide capable of controlling the expression of INOS and composition comprising the same | |
| Georgiev | Precursor of mRNA (Pre-mRNA) | |
| KR20180002528A (en) | Compounds improving RNA interference of small interfering RNA and use thereof | |
| Dolnick | Naturally occurring antisense RNA | |
| CN117413065A (en) | Constructs, methods and uses for the preparation of circular RNAs | |
| Björklund et al. | An S‐phase specific release from a transcriptional block regulates the expression of mouse ribonucleotide reductase R2 subunit. | |
| US20150376670A1 (en) | Dna templates for small rna production in mammalian cells | |
| CA3218778A1 (en) | Modified mrna, modified non-coding rna, and uses thereof | |
| KR20220122727A (en) | Novel method for targeted editing of RNA | |
| CN110241136B (en) | Small molecule compound for promoting gene editing and application thereof | |
| Vidaček et al. | Abrupt telomere shortening in normal human fibroblasts | |
| CN116555339B (en) | NHEJ substrate and preparation method and application thereof | |
| US8975023B2 (en) | Method for controlling the amount of gene product, and agent for controlling the amount of gene product | |
| US20220275378A1 (en) | Method for the generation of dumbbell-shaped dna vectors | |
| CN116322791A (en) | Modified functional nucleic acid molecules | |
| US8323975B2 (en) | Telomere-encoding synthetic DNA nanocircles, and their use for the elongation of telomere repeats | |
| CN112080498A (en) | siRNA of targeting PLK1 and application thereof in preparing tumor treatment medicine | |
| Hardy | Human cleavage factor I (CFIm) and its role in alternative polyadenylation of pre-mRNA | |
| CN111057717A (en) | Method for rapidly preparing gRNA expression vector capable of being directly used and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |